To the Huntington’s Disease community around the world; Do not lose HOPE.
A couple of weeks ago, I had the pleasure to talk with Henk Schuring Chief Regulatory & Commercialization Officer about Prilenia; a clinical stage biotech company, led by Michael Hayden, MD, PhD., together with a highly experienced team with a track record of success. Michael is a world-renowned scientist in Huntington Disease research.
Henk found my Huntington’s disease (HD) Advocacy & Author website and emailed me.
It’s a very exciting time since Prilenia is in Phase 3 of a clinical trial on the drug, Pridopidine, an oral drug currently in development for the treatment of Huntington’s disease and ALS. It is administered in a small easy-to-swallow capsule twice a day.
Prilenia participated in 2021 HDSA Convention. They were in the Exhibit Hall last June.
Clinical trials on pridopidine are being conducted in two (2) locations in California. They are:
We Can Never Lose HOPE…